Kazia Therapeutics Limited was delisted from the Official List of the Australian Securities Exchange at the close of trading on Wednesday 15 November 2023. This means Kazia's fully paid ordinary shares are no longer tradeable on the ASX. Kazia's sole listing is now on NASADQ and its securities are only tradeable as American Depositary Shares (ADSs).
Shareholders who have requested to convert under the ADS conversion facility will be issued with ADSs and will receive their transaction advice and a welcome letter from Computershare USA. A thorough procedure has to be followed as part of the conversion process, so this transaction advice and welcome letter will be received by shareholders by approximately late December to early-January.
If you did not participate in the conversion facility or participated in respect of only a portion of your shareholding (i.e. custodians/nominees and shareholders with a number of shares not divisible by the 10:1 share/ADS ratio), you will receive a share certificate by approximately late December to early-January. This must be kept in a safe place as it is proof of ownership of Shares in the Company.
Unfortunately, there was an unexpected delay with the despatch of the ADS documentation and it was posted by Computershare US on 18 December 2023. Please allow additional time to receive this documentation given the impact of the holiday season on postage.
If you have not received your transaction advice or share certificate by Monday 15 January 2024, please contact Computershare in the US:
US toll free: +1 866 247 4146
Tel: +1 201 680 6825